Department of Pathology and Laboratory Medicine, Western University, London, ON, N6A 3K7, Canada.
Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
Eur J Hum Genet. 2023 Aug;31(8):879-886. doi: 10.1038/s41431-023-01313-z. Epub 2023 Feb 16.
The challenges and ambiguities in providing an accurate diagnosis for patients with neurodevelopmental disorders have led researchers to apply epigenetics as a technique to validate the diagnosis provided based on the clinical examination and genetic testing results. Genome-wide DNA methylation analysis has recently been adapted for clinical testing of patients with genetic neurodevelopmental disorders. In this paper, preliminary data demonstrating a DNA methylation signature for Renpenning syndrome (RENS1 - OMIM 309500), which is an X-linked recessive neurodevelopmental disorder caused by variants in polyglutamine-binding protein 1 (PQBP1) is reported. The identified episignature was then utilized to construct a highly sensitive and specific binary classification model. Besides providing evidence for the existence of a DNA methylation episignature for Renpenning syndrome, this study increases the knowledge of the molecular mechanisms related to the disease. Moreover, the availability of more subjects in future may facilitate the establishment of an episignature that can be utilized for diagnosis in a clinical setting and for reclassification of variants of unknown clinical significance.
为神经发育障碍患者提供准确诊断所面临的挑战和不确定性促使研究人员将表观遗传学作为一种技术,用于验证基于临床检查和基因测试结果提供的诊断。全基因组 DNA 甲基化分析最近已被应用于遗传神经发育障碍患者的临床检测。本文报告了初步数据,表明 Renpenning 综合征(RENS1-OMIM 309500)存在 DNA 甲基化特征,该综合征是一种由多聚谷氨酰胺结合蛋白 1(PQBP1)变异引起的 X 连锁隐性神经发育障碍。然后利用鉴定的表观遗传特征构建了一个高灵敏度和特异性的二分类模型。除了为 Renpenning 综合征存在 DNA 甲基化表观遗传特征提供证据外,本研究还增加了对与疾病相关的分子机制的认识。此外,未来可能会有更多的研究对象,有助于建立一种可用于临床诊断和未知临床意义变异再分类的表观遗传特征。